• Explore /
  • Poster
  • / Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Abstract Poster

Authors

null

Priyanka Sharma

University of Kansas Medical Center, Kansas City, KS

Priyanka Sharma , Vandana Gupta Abramson , Anne O'Dea , Harsh B Pathak , Ziyan Y. Pessetto , Yen Y. Wang , Karissa Finke , Marc Steven Hoffmann , Manana Elia , Sharon Lewis , Jecinta Scott , Jilliann De Jong , Julia Urban , Jaimie Heldstab , Stephanie LaFaver , Stephen K. Williamson , Greg Reed , Bruce F. Kimler , Qamar J. Khan , Andrew K. Godwin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT02379247

Citation

J Clin Oncol 36, 2018 (suppl; abstr 1018)

DOI

10.1200/JCO.2018.36.15_suppl.1018

Abstract #

1018

Poster Bd #

99

Abstract Disclosures

Similar Posters

First Author: Cristina I. Truica

First Author: Cesar Augusto Perez

Poster

2020 ASCO Virtual Scientific Program

Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.

Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.

First Author: Jing Shan Lim

First Author: Dejan Juric